EveliQure is an innovative biotech company developing novel vaccines for the prevention of diarrheal diseases affecting travelers and young children living in developing countries. ShigETEC, our first product candidate in development, is aimed at providing protection against both Shigella and ETEC. Based on our proprietary live attenuated Shigella vaccine strain it induces broad protection against shigellosis, but also producing protective ETEC antigens, the two diarrhogenic toxins, LT and ST.